Anthera Pharmaceuticals, Inc. (ANTH)

[Paulieme]

Anthera Pharmaceuticals Inc (ANTH) Sets New 1-Year Low at $2.28
Posted by Joseph Griffin on Feb 8th, 2016 --- Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) reached a new 52-week low during trading on Monday , Marketbeat reports. The company traded as low as $2.28 and last traded at $2.34, with a volume of 591,284 shares. The stock had previously closed at $2.67.
Separately, Zacks Investment Research downgraded Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 5th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Anthera Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $11.85.
The stock’s market capitalization is $98.09 million. The firm’s 50-day moving average price is $3.64 and its 200-day moving average price is $6.21.


In other news, insider Colin Hislop sold 12,500 shares of the company’s stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $5.31, for a total value of $66,375.00. Following the transaction, the insider now owns 19,147 shares in the company, valued at approximately $101,670.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
A hedge fund recently raised its stake in Anthera Pharmaceuticals stock. California State Teachers Retirement System boosted its position in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) by 1.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,476 shares of the biopharmaceutical company’s stock after buying an additional 1,263 shares during the period. California State Teachers Retirement System owned approximately 0.18% of Anthera Pharmaceuticals worth $341,000 at the end of the most recent reporting period.
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others.
http://www.tickerreport.com/banking-finance/1364912/anthera-pharmaceuticals-inc-anth-sets-new-1-year-low-at-2-28/